87 results about "Furanose" patented technology

Described herein are novel gene sequences isolated from Trichoderma reesei. Two genes encoding proteins comprising a cellulose binding domain, one encoding an arabionfuranosidase and one encoding an acetylxylanesterase are described. The sequences, CIP1 and CIP2, contain a cellulose binding domain. These proteins are especially useful in the textile and detergent industry and in pulp and paper industry.cip1 cDNA sequence (SEQ ID NO: 1)GACTAGTTCA TAATACAGTA GTTGAGTTCA TAGCAACTTC50TGAACAAATT ATCTGCGCAA ACATGGTTCG CCGGACTGCT100CTGCTGGCCCTTGGGGCTCT CTCAACGCTC TCTATGGCCC AAATCTCAGA150CGACTTCGAGTCGGGCTGGG ATCAGACTAA ATGGCCCATT TCGGCACCAG200ACTGTAACCAGGGCGGCACC GTCAGCCTCG ACACCACAGT AGCCCACAGC250GGCAGCAACTCCATGAAGGT CGTTGGTGGC CCCAATGGCT ACTGTGGACA300CATCTTCTTCGGCACTACCC AGGTGCCAAC TGGGGATGTA TATGTCAGAG350CTTGGATTCGGCTTCAGACT GCTCTCGGCA GCAACCACGT CACATTCATC400ATCATGCCAGACACCGCTCA GGGAGGGAAG CACCTCCGAA TTGGTGGCCA450AAGCCAAGTTCTCGACTACA ACCGCGAGTC CGACGATGCC ACTCTTCCGG500ACCTGTCTCCCAACGGCATT GCCTCCACCG TCACTCTGCC TACCGGCGCG550TTCCAGTGCTTCGAGTACCA CCTGGGCACT GACGGAACCA TCGAGACGTG600GCTCAACGGCAGCCTCATCC CGGGCATGAC CGTGGGCCCT GGCGTCGACA650ATCCAAACGACGCTGGCTGG ACGAGGGCCA GCTATATTCC GGAGATCACC700GGTGTCAACTTTGGCTGGGA GGCCTACAGC GGAGACGTCA ACACCGTCTG750GTTCGACGACATCTCGATTG CGTCGACCCG CGTGGGATGC GGCCCCGGCA800GCCCCGGCGGTCCTGGAAGC TCGACGACTG GGCGTAGCAG CACCTCGGGC850CCGACGAGCACTTCGAGGCC AAGCACCACC ATTCCGCCAC CGACTTCCAG900GACAACGACCGCCACGGGTC CGACTCAGAC ACACTATGGC CAGTGCGGAG1000GGATTGGTTACAGCGGGCCT ACGGTCTGCG CGAGCGGCAC GACCTGCCAG1050GTCCTGAACCCATACTACTC CCAGTGCTTA TAAGGGGATG AGCATGGAGT1100GAAGTGGAGA GAGTTGAAGT GGCATTGCGC TCGGCTGGGT1150CAGCAGCTAT GAATACTCTA TGTGATGCTC ATTGGCGTGT1200AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA1250AAAAAAAAAG GGGGCGGCCG C1271

The invention concerns a new lipoteichoic acid which can be isolated from the new Streptococcus sp DSM 8747. The new LTA is called LTA-T. It has a lipid anchor, which is a galacto-furanosyl-beta-1-3-glycerol with different rests of fatty acids esterified in the two adjacent hydroxy groups in the glycerol moiety and a non-glycosylated, linear, unbranched GroP chain with an unusual short hydrophilic GroP chain. The hydrophilic backbone consists of only 10 glycerophosphate units esterified with D-alanine in an extent of 30%. The invention further concerns a pharmaceutical composition with the new LTA-T, optionally together with a monokine and / or hyaluronidase, a method of treating cancer comprising administration of an antitumor effective amount thereof, a method of producing the new compound and the new pharmaceutical composition, two degradation products of the new LTA-T and their use, and the new Streptococcus strain from which the new compound can be isolated.

Described herein are novel gene sequences isolated from Trichoderma reesei. Two genes encoding proteins comprising a cellulose binding domain, one encoding an arabionfuranosidase and one encoding an acetylxylanesterase are described. The sequences, CIP1 and CIP2, contain a cellulose binding domain. These proteins are especially useful in the textile and detergent industry and in pulp and paper industry.

An improved process for the preparation of 2'-modified nucleosides and 2'-deoxy-nucleosides, such as, beta-L-2'-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2'-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2' anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2'-anhydro-1-furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2'-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2'-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and / or antineoplastic agents.

The invention discloses an eye drop for treating eye dryness. The pH value of the eye drop is 5.0-7.0, the eye drop comprises effective components of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, and specifically the eye drop consists of the following components in percentage by weight: 0.05-0.1% of 5-hydroxy-1-beta-D-furanose-1H-imidazole-5-carboxamide, a proper amount of a pH value adjusting agent, 0.01-3% of an iso-osmotic agent, 0.003-0.5% of a bacteriostatic agent, 0.001-0.5% of a stabilizer, 0.01-0.5% of a tackifier, 2-5% of a solubilizer and the balance of water. Through partial treatment of the eye drop, epithelial barrier functions of dry eye mouse cornea can be protected, the number of goblet cells of cornea can be recovered, and relatively good anti-inflammatory and immunity inhibition effects can be achieved.

The invention relates to the field of gene engineering, in particular to a high temperature-resistant acid arabinfuranosidease AbfaHLB and a gene and an application thereof. The arabinfuranosidease AbfaHLB comes from bacillus badius HLB, an amino acid sequence is shown in SEQ ID No.1, and an encoding gene abfa HLB for encoding the arabinfuranosidease AbfaHLB is provided. The arabinfuranosidease has the advantages that the following properties are realized, the suitable pH (potential of hydrogen) value is 4.5, the suitable temperature is 50 DEG C, and the thermal stability at the temperature of 80 DEG C is good; the arabinfuranosidease is used as a new enzyme preparation, and can be widely applied to feeds, foods, energy source industry and the like.

A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-β-d-xylanase) and a β-glucanase (and optionally a further fibre degrading enzyme), wherein the DFM is selected from the group consisting of an enzyme producing strain; a C5 sugar-fermenting strain; a short-chain fatty acid-producing strain; a fibrolytic, endogenous microflora-promoting strain; or combinations thereof. The DFM may be selected from the group consisting of: Bacillus subtilis AGTP BS3BP5, Bacillus subtilis AGTP BS442, B. subtilis AGTP BS521, B. subtilis AGTP BS918, Bacillus subtilis AGTP BS1013, B. subtilis AGTP BS1069, B. subtilis AGTP 944, B. pumilus AGTP BS 1068 or B. pumilus KX11-1, Enterococcus faecium ID7, Propionibacterium acidipropionici P169, Lactobacillus rhamnosus CNCM-I-3698, Lactobacillus farciminis CNCM-I-3699, a strain having all the characteristics thereof, any derivative or variant thereof, and combinations thereof and the further fibre degrading enzyme may be selected from the group consisting of a cellobiohydrolase (E.C. 3.2.1.176 and E.C. 3.2.1.91), a β-glucosidase (E.C. 3.2.1.21), a β-xylosidase (E.C. 3.2.1.37), a feruloyl esterase (E.C. 3.1.1.73), an α-arabinofuranosidase (E.C. 3.2.1.55), a pectinase (e.g. an endopolygalacturonase (E.C. 3.2.1.15), an exopolygalacturonase (E.C. 3.2.1.67) or a pectate lyase (E.C. 4.2.2.2)), or combinations thereof.

The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer.Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer.Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

The invention discloses a 4-amino-acid-substituted pyrimidine nucleoside compound and a synthesis method and medicinal application thereof and belongs to the field of medicinal chemistry. The compoundhas a structure shown as a formula (I) which is described in the description, wherein in the formula (I), R1 refers to H, CH3, CH2CH3, K and Na, R2 refers to H, CH3, CH2CH3, K and Na, and when R1 andR2 do not represent CH3 at the same time, L-glutamic acid dimethyl ester in 4-(L-glutamic acid dimethyl ester)-1-(2'-deoxidized-2'-beta-fluoro-4'-alpha-nitrine-beta-D-furan glycosyl)cytosine is modified, so that a series of 4-amino-acid-substituted pyrimidine nucleoside derivatives are synthesized, and these compounds have the activity of resisting Coxsackie virus 3. A preparation method is feasible, and the 4-amino-acid-substituted pyrimidine nucleoside compound is applied to drugs for treating viral myocarditis and has a great application prospect.

The invention discloses a regulatory protein AraR mutant synthesized by fungus alpha-L-arabinofuranosidase. The mutant is obtained by mutating regulatory protein 731st alanine with an amino acid sequence as shown in SEQ ID NO.1 into valine, the amino acid sequence of the mutant is as shown in SEQ ID NO.2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO.3. The invention alsodiscloses an application of the regulatory protein mutant in the production of alpha-L-arabinofuranosidase and alpha-galactosidase. Experiments confirm that the yield of alpha-L-arabinofuranosidase and alpha-galactosidase can be greatly enhanced by expressing the regulatory protein mutant in a fungal strain.

Patients suffering from cancer are treated by being administered a compound represented by the following formula: wherein each R individually is H or an aliphatic or aromatic acyl group; A is selected from the group consisting of wherein X is selected from the group consisting of hydrogen, fluorine, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro. The above compounds also inhibit DNA replication in mammalian cells.

The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a beta-xylosidase, an arabinofiiranosidase, and / or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, beta-xylosidase, arabinofuranosidase, and / or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention.

A first aspect of the invention relates to a combination comprising 2'-cyano-2'-deoxy-N4-palmitoyl-l-beta-D-arabinofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from (a) a vinca alkaloid; (b) a taxane; (c) a cytosine analogue; (d) an anthracycline; and (e) a platinum antineoplastic agent. A second aspect of the invention relates to a pharmaceutical product comprising the above combination as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering the above combination.

Nucleoside analogues wherein a 2'-4'-bridge locks the conformation of the nucleoside have been synthesised with an inverted stereochemistry at C-3' and C-4' to provide the L-ribo-configurated LNA nucleoside. The synthesis of L-ribo-LNA-nucleoside is applicable to all nucleobases including thymine, adenine, cytosine, guanine and uracil. These Locked Nucleic Acids (LNAs) with L-ribo-configuration have been utilised in the synthesis of 2'-O-4'-C-methylene- alpha -L-ribofuranosyl nucleotides as well as oligonucleotides with L-ribo-LNA nucleosides included therein. Methods of targeting complementary nucleic acids are greatly improved by use of these L-ribo-LNA modified oligonucleotides due to their high affinity for complementary nucleic acids.